Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Leukemia. 2019 May 24;33(12):2805–2816. doi: 10.1038/s41375-019-0491-z

Figure 6. ONC212 and ABT-199 combination treatment synergistically decreases AML propagation in vivo.

Figure 6.

(A) Serial bioluminescence images of mice bearing MOLM13-Luc treated with the solvent, ONC212 (50 mg/kg; 3 times/wk), ABT-199 (100 mg/kg; daily) and combination treatment (treatment started on d three administered by oral gavage). (B) Kaplan–Meier survival curves for mice as described above (n = 10). The survival of the mice was remarkably prolonged by ONC212 and ABT-199 oral gavage treatment. (C) Body weight of mice bearing MOLM13-Luc treated with the solvent, ONC212, ABT-199 and combination treatment (n = 10).